New Biomarkers for Organ Viability Assessment During Hypothermic Machine Perfusion in Liver Transplantation: the Role of Extemporaneous Histological Examination. (LOVE)
Liver transplantation is a life-saving treatment for patients with severe liver disease. Because of the shortage of donor organs, transplant centers increasingly use donor livers that may be more vulnerable to injury and dysfunction. To improve the quality of these organs before transplantation, many centers use hypothermic oxygenated machine perfusion (HOPE or D-HOPE), a technique that preserves the liver under cold, oxygenated conditions. However, there are currently no widely accepted methods to determine whether a liver is functioning well enough during this preservation process.
The purpose of this study is to investigate whether changes observed in liver tissue during hypothermic machine perfusion can help predict how well the transplanted liver will function after surgery. The study will compare liver biopsy samples collected before and after one hour of perfusion and will analyze biological markers released into the perfusion fluid, including markers of mitochondrial injury and inflammation.
The main question this study aims to answer is whether histological changes occurring during hypothermic perfusion, alone or in combination with biochemical biomarkers, can accurately predict liver graft viability and post-transplant outcomes. Researchers will also evaluate whether these data can be used to develop an artificial intelligence-based model to support clinical decision-making during organ preservation.
A total of 150 adult liver transplant recipients receiving donor livers treated with HOPE or D-HOPE will be enrolled at three Italian liver transplant centers. Participants will be followed for 90 days after transplantation to assess liver graft function, graft survival, patient survival, and post-transplant complications.
The results of this study may improve the assessment of donor liver quality before transplantation and help clinicians make more informed decisions about organ use, ultimately increasing the safety and effectiveness of liver transplantation.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Ivan Vella
- Numero di telefono: +39 3803403369
- Email: ivella@ismett.edu
Backup dei contatti dello studio
- Nome: Monica Rizzo
- Numero di telefono: +39 0912192692
- Email: ufficioricerca@ismett.edu
Luoghi di studio
-
-
-
Milan, Italia, 20162
- ASST Grande Ospedale Metropolitano Niguarda
-
Palermo, Italia, 90127
- IRCCS ISMETT - Istituto Mediterraneo per i Trapianti e le Terapie ad Alta Specializzazione,
-
Contatto:
- Ivan Vella
- Numero di telefono: +39 3803403369
- Email: ivella@ismett.edu
-
Contatto:
- Monica Rizzo
- Numero di telefono: +39 0912192692
- Email: ufficioricerca@ismett.edu
-
Investigatore principale:
- Ivan Vella
-
Roma, Italia, 00152
- Azienda Ospedaliera San Camillo Forlanini
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Adult liver transplant recipients (≥18 years of age).
- Donor liver grafts from either Donation after Brain Death (DBD) or Donation after Circulatory Death (DCD).
- Grafts undergoing hypothermic oxygenated perfusion (HOPE) (HOPE or D-HOPE) for a minimum duration of 1 hour prior to transplantation.
- Availability of two wedge liver biopsy samples: one pre perfusion and one post-perfusion.
- Grafts preserved using standard cold storage protocols and transported in ice-cold Servator C™ solution.
- Informed consent obtained from the recipient (or legal representative, where applicable) for the use of clinical and histological data for research purposes.
Exclusion Criteria:
- Inadequate or fragmented biopsy samples, preventing proper histological evaluation.
- Biopsy samples showing histological features of pre-existing chronic liver disease (e.g., cirrhosis, autoimmune hepatitis, chronic viral hepatitis).
- Liver grafts subjected to normothermic perfusion or other non hypothermic perfusion techniques.
- Organs undergoing experimental or non-standard perfusion protocols.
- Grafts from donors <18 years of age.
- Recipient refusal or inability to provide informed consent.
- Technical failure during perfusion (e.g., incomplete perfusion due to device malfunction or vascular anomalies).
- Known malignancy in the donor with potential liver involvement, excluding donors with small incidentalomas as per standard guidelines.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Diagnostico
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: HOPE/D-HOPE Liver Transplant Recipients
Adult liver transplant recipients receiving donor liver grafts preserved with hypothermic oxygenated machine perfusion (HOPE or D-HOPE) prior to transplantation.
Liver biopsies and perfusate samples are collected before and during perfusion for histological and biomarker analyses, and participants are followed for 90 days after transplantation.
|
Standard-of-care hypothermic oxygenated machine perfusion of donor liver grafts before transplantation, with collection of biopsies and perfusate samples for research analyses.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Graft Survival
Lasso di tempo: 90 days after liver transplantation
|
Graft survival defined as the absence of Early Allograft Dysfunction (EAD) or Primary Non-Function (PNF) following liver transplantation.
Histological changes observed between pre-perfusion and post-perfusion liver biopsies will be evaluated for their association with graft outcomes.
|
90 days after liver transplantation
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- IRRB/13/26
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Disfunzione precoce dell'allotrapianto
-
Western University, CanadaNon ancora reclutamentoeTRE (Early Time Restricted Eating) con BCAA | eTRE (Early Time Restricted Eating)Canada
-
Western University, CanadaSconosciutoeTRE (Early Time Restricted Eating) | lTRE (Late Time Restricted Eating)Canada
-
Western University, CanadaNon ancora reclutamentoeTRE (Early Time Restricted Eating) | eTRE Con BISC (Arrampicata Breve Intensa su Scale)Canada
Prove cliniche su Hypothermic Oxygenated Machine Perfusion (HOPE/D-HOPE)
-
Azienda Ospedaliero-Universitaria di ModenaReclutamentoCarcinoma epatocellulare | Trapianto di fegato; ComplicazioniItalia